Rhythm Pharmaceuticals, Inc. announced that it will present clinical data from its two pivotal Phase 3 clinical trials evaluating setmelanotide for the treatment of pro-opiomelanocortin and leptin receptor deficiency obesities, as well as preclinical data characterizing missense variants within the melanocortin-4 receptor pathway, during the 37th Annual Meeting of The Obesity Society at ObesityWeek® 2019, Nov. 3-7, at Mandalay Bay South Convention Center in Las Vegas.
October 30, 2019
· 4 min read